Ivonescimab+chemo extends survival in first-line squamous NSCLC at ASCO

Akeso’s ivonescimab, a PD-1xVEGF bispecific, plus chemotherapy significantly extended overall survival in first-line, untreated squamous NSCLC in the Harmoni-6 trial, cutting death risk by 34% with a median OS of 27.9 months vs 23.7 months (p=0.0017) versus Tevimbra-chemo. The interim China-only ASCO presentation showed benefit across PD-L1–negative and –positive patients, but experts caution the follow-up is immature and point to safety signals and trial eligibility criteria that may limit global applicability, signaling a need for further studies.